Acetylcholinesterase Inhibitors are drugs which limit the activity of the enzyme acetylcholinesterase. Acetylcholinesterase (AChE) is an enzyme which breaks down the neurotransmitter acetylcholine (ACh) into its component parts. AChE inhibitors therefore increase the amount of ACh in the synapse, the area between brain cells where information is transmitted, and interact with a variety of receptors including cholinergic nicotinic receptors. This activity means AChE inhibitors can have a wide range of therapeutic effects. There are several medical uses for AChE inhibitors. The most well-known is in the treatment of Alzheimer's disease, where it is believed that reducing AChE activity helps prevent the breakdown of ACh, leading to increased activity in the hippocampus. In addition, AChE inhibitors have been studied in the treatment of Parkinson's disease, schizophrenia, chronic pain, and depression and may help improve cognitive function in patients with dementia. AChE inhibitors also have other non-medical applications. They are used as organophosphate pesticides, such as malathion, to control insects. Additionally, during dietary changes or fasting periods, AChE inhibitors can cause a stimulation of the ingestion of food due to increased activity in the areas of the brain responsible for hunger. The effects of AChE inhibitors may vary depending on the individual. Common side effects may include nausea, vomiting, diarrhoea, increased salivation, muscle weakness, tremors, dizziness, headache, and confusion. Rarely, AChE inhibitors can cause a decrease in white blood cells, leading to infection, or life-threatening breathing difficulties. Therefore, it is important to consult with a doctor or pharmacist if any of these symptoms occur. In conclusion, acetylcholinesterase inhibitors are useful drugs for a range of medical and non-medical applications. They can be helpful in reducing the degradation of acetylcholine and increasing synaptic activity, but they may also have side effects. Therefore, it is important that they be used with caution and only under the guidance of a medical professional.
Title : A case of vile vindictive primary CNS vasculitis
George Diaz, Memorial Healthcare Systems, United States
Title : Novel important cellular responses, signaling mechanisms and therapeutic options in vascular dementia
Yong Xiao Wang, Albany Medical College, United States
Title : The role of beliefs, perception, and behavioural patterns in the evolution of psychophysical disorders
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Narrative medicine: A communication therapy for the communication disorder of Functional Seizures (FS) [also known as Psychogenic Non-Epileptic Seizures (PNES)]
Robert B Slocum, University of Kentucky HealthCare, United States
Title : How have we eliminated infection: From the bone to brain ?
Thomas J Webster, Interstellar Therapeutics, United States
Title : Cervical stenosis-induced chronic cerebrospinal fluid flow restriction as a contributing cause of dementia
Joe Sam Robinson, Mercer University, United States